Evotec AG (EVOTF.PK,EVTCY.PK) Friday said it has received a milestone payment from Ono Pharmaceutical Co., Ltd. (OPHLF.PK), for the development of a compound which has been nominated to enter pre-clinical development.
The compound was identified and optimised in a research collaboration, initiated in March 2008, with Ono.
Kazuhito Kawabata, Managing Director, Research Headquarters at Ono, said “This pre-clinical candidate is an important member of our development pipeline and we have high expectations for it. During the entire project we could count on the access to various technologies and on the knowledge, but in particular on the drug discovery expertise of our colleagues from Evotec. ”
Click here to receive FREE breaking news email alerts for Evotec AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News